VRAX · Virax Biolabs Group Ltd · Shareholders & Ownership
Every disclosed holder of VRAX in one list: 13F institutions, Schedule 13D and 13G filers, insiders (Forms 3, 4 and 5) and registered funds, each from its own latest filing. Holders nest by CIK and SEC reporting links, never by name, and each is summed once.
Who Owns VRAX
13F quarter Jun 30, 2026No chart: shares outstanding cannot be set against these holders.
| Holder group | Shares | % Out |
|---|---|---|
| Institutional (13F) | 26,389 | — |
| Insiders (Forms 3, 4, 5) | 11,519 | — |
| 13D/G-only blocks | 40,010 | — |
| Registered funds (N-PORT, not summed) | 0 | — |
% Out is unavailable: a foreign private issuer reports ordinary shares, a different unit from the listed shares.
13D/G-only counts each filer's latest 13D or 13G that no 13F report of the listing contains, that names no 13F filer and that no counted insider files. Funds are never summed: their shares sit inside their advisers' 13F reports.
Holders of VRAX
| # | Holder | Shares | As of | Notes |
|---|---|---|---|---|
| 1 |
ARMISTICE CAPITAL, LLC
13G
CIK 1601086 · Registered investment adviser · Mar 31, 2026
Rule 13d-1(b), qualified institution
|
40,010 | ||
| 2 |
JANE STREET GROUP, LLC
13F
CIK 1595888 · Unknown · Jun 30, 2026
|
26,385 | ||
| 3 |
Foster James Alexander Cunliffe
Insider
CIK 1988784 · Mar 18, 2026
Chief Executive Officer, issuer-wide
|
11,519 | ||
| 3.1 |
|
14,743 | ||
| 4 |
UBS Group AG
13F
CIK 1610520 · Bank · Jun 30, 2026
|
4 |
Shares are restated onto today's split basis. Change compares each row with the same holder's previous filing in the same source; a dash means there is none to compare. Nested 13D/G, insider and fund rows are not summed, since a 13F report already holds them.